A Phase 1, Open-label, Sequential Study to Investigate the Pharmacokinetic Interaction Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2018
At a glance
- Drugs Dabigatran etexilate (Primary) ; Odalasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 01 May 2017 Planned End Date changed from 1 Jan 2017 to 12 Jan 2017.
- 01 May 2017 Planned primary completion date changed from 1 Jan 2017 to 9 Jan 2017.